Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation

Mapping Intimacies ◽

10.1158/1538-7445.panca2014-b102 ◽

2015 ◽

Cited By ~ 1

Author(s):

Susan M. Domchek ◽

Robert McWilliams ◽

Andrew Hendifar ◽

Rachna T. Shroff ◽

Lawrence Leichman ◽

...

Keyword(s):

Pancreatic Cancer ◽

Brca Mutation ◽

Parp Inhibitor ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps4161 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS4161-TPS4161

Author(s):

Susan M. Domchek ◽

Robert R. McWilliams ◽

Andrew Eugene Hendifar ◽

Rachna T. Shroff ◽

Lawrence P. Leichman ◽

...

Keyword(s):

Pancreatic Cancer ◽

Brca Mutation ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)

10.1136/ijgc-2019-igcs.312 ◽

2019 ◽

Author(s):

K Moore ◽

K Redhead ◽

S Goble ◽

O Bowles ◽

KK Lin ◽

...

Keyword(s):

Urothelial Cancer ◽

Parp Inhibitor ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

ARIES: A PHASE 2, OPEN-LABEL STUDY TO EVALUATE RUCAPARIB (PARP INHIBITOR) IN COMBINATION WITH NIVOLUMAB (ANTI-PD-1 ANTIBODY) IN PATIENTS WITH OVARIAN OR UROTHELIAL CANCER (UC)

10.26226/morressier.5d2ee8eb1e09a6f49485ac6b ◽

2019 ◽

Author(s):

Kathleen Moore

Keyword(s):

Urothelial Cancer ◽

Parp Inhibitor ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4110 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4110-4110 ◽

Cited By ~ 17

Author(s):

Susan M. Domchek ◽

Andrew Eugene Hendifar ◽

Robert R. McWilliams ◽

Ravit Geva ◽

Ron Epelbaum ◽

...

Keyword(s):

Pancreatic Cancer ◽

Brca Mutation ◽

Parp Inhibitor ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

Cancer Medicine ◽

10.1002/cam4.137 ◽

2013 ◽

Vol 2 (6) ◽

pp. 925-932 ◽

Cited By ~ 51

Author(s):

Andres Forero-Torres ◽

Jeffrey R. Infante ◽

David Waterhouse ◽

Lucas Wong ◽

Selwyn Vickers ◽

...

Keyword(s):

Pancreatic Cancer ◽

Monoclonal Antibody ◽

Death Receptor ◽

Metastatic Pancreatic Cancer ◽

Death Receptor 5 ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Humanized Monoclonal Antibody

Download Full-text

Faculty Opinions recommendation of Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717797810.793153212 ◽

2012 ◽

Author(s):

Klaus Klaushofer

Keyword(s):

Bone Mineral Density ◽

Back Pain ◽

Bone Mineral ◽

Phase 2 ◽

Mineral Density ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia

Pediatric Blood & Cancer ◽

10.1002/pbc.28946 ◽

2021 ◽

Author(s):

Maureen M. O'Brien ◽

Todd A. Alonzo ◽

Todd M. Cooper ◽

John E. Levine ◽

Patrick A. Brown ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Refractory Acute Myeloid Leukemia ◽

Acute Myeloid

Download Full-text

Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China

Annals of Hematology ◽

10.1007/s00277-018-3488-1 ◽

2018 ◽

Vol 98 (1) ◽

pp. 143-150 ◽

Cited By ~ 1

Author(s):

Yan Zhang ◽

Wei Zhang ◽

Jian Li ◽

Minghui Duan ◽

Bing Han ◽

...

Keyword(s):

T Cell ◽

Cell Lymphoma ◽

T Cell Lymphoma ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Center ◽

Open Label ◽

Peripheral T Cell Lymphoma ◽

Open Label Study ◽

Label Study

Download Full-text

Abstract OT-32-01: A phase 2, open-label study of bintrafusp alfa monotherapy in patients withHMGA2-expressing triple-negative breast cancer

10.1158/1538-7445.sabcs20-ot-32-01 ◽

2021 ◽

Author(s):

Leisha A Emens ◽

Margaret E. Gatti-Mays ◽

Joyce O’Shaughnessy ◽

Luc Dirix ◽

Giovanni Faggioni ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)

Annals of Oncology ◽

10.1016/j.annonc.2020.04.064 ◽

2020 ◽

Vol 31 ◽

pp. 235

Author(s):

K. Yamaguchi ◽

Y. Bang ◽

S. Iwasa ◽

N. Sugimoto ◽

M. Ryu ◽

...

Keyword(s):

Gastroesophageal Junction ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Gastroesophageal Junction Adenocarcinoma ◽

O 11 ◽

Randomized Phase 2

Download Full-text